Hualien, Taiwan

Chia-Yu Chang

USPTO Granted Patents = 1 

Average Co-Inventor Count = 10.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovator Spotlight: Chia-Yu CHANG - Pioneering Advances in Amyotrophic Lateral Sclerosis Treatment

Introduction: Chia-Yu CHANG, a distinguished inventor hailing from Hualien, Taiwan, is revolutionizing the field of medical treatment with his groundbreaking patent for the prevention and treatment of amyotrophic lateral sclerosis (ALS). His pioneering work has the potential to significantly impact the lives of ALS patients worldwide.

Latest Patents: Chia-Yu CHANG holds a significant patent titled "Method for prevention or treatment of amyotrophic lateral sclerosis by administering gastrodin," which introduces a pharmaceutical composition including gastrodin for the prevention and treatment of ALS. This composition has shown promising results in reducing neuronal axon degeneration, neurofibromin accumulation, improving symptoms, and extending the lives of ALS patients.

Career Highlights: As a key member of the Buddhist Tzu Chi Medical Foundation, Chia-Yu CHANG has utilized his expertise to drive forward innovative medical solutions. His dedication to advancing ALS treatment has earned him recognition as a leading figure in the field of neurology and pharmaceuticals.

Collaborations: Throughout his career, Chia-Yu CHANG has collaborated closely with esteemed colleagues such as Shinn-Zong LIN and Hsiao-Chien TING. Together, they have worked tirelessly to further the research and development of novel treatments for neurological disorders, including ALS.

Conclusion: In conclusion, Chia-Yu CHANG's passion for innovation and his relentless pursuit of medical advancements make him a trailblazer in the field of ALS treatment. His contributions have the potential to transform the lives of ALS patients and pave the way for future breakthroughs in neurological medicine.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…